Polycystic ovary syndrome (PCOS), characterized by increased ovarian androgen biosynthesis, anovulation, and infertility, affects 5-7% of reproductive-age women. Genome-wide association studies identified PCOS candidate loci that were replicated in subsequent reports, including DENND1A, which encodes a protein associated with clathrin-coated pits where cell-surface receptors reside. However, these studies provided no information about functional roles for DENND1A in the pathogenesis of PCOS. DENND1A protein was located in the cytoplasm as well as nuclei of theca cells, suggesting a possible role in gene regulation. DENND1A immunostaining was more intense in the theca of PCOS ovaries. Using theca cells isolated and propagated from normal cycling and PCOS women, we found that DENND1A variant 2 (DENND1A.V2) protein and mRNA levels are increased in PCOS theca cells. Exosomal DENND1A.V2 RNA was significantly elevated in urine from PCOS women compared with normal cycling women. Forced overexpression of DENND1A.V2 in normal theca cells resulted in a PCOS phenotype of augmented CYP17A1 and CYP11A1 gene transcription, mRNA abundance, and androgen biosynthesis. Knock-down of DENND1A.V2 in PCOS theca cells reduced androgen biosynthesis and CYP17A1 and CYP11A1 gene transcription. An IgG specific to DENND1A.V2 also reduced androgen biosynthesis and CYP17 and CYP11A1 mRNA when added to the medium of cultured PCOS theca cells. We conclude that the PCOS candidate gene, DENND1A, plays a key role in the hyperandrogenemia associated with PCOS. These observations have both diagnostic and therapeutic implications for this common disorder. P olycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5-7% of reproductive age women world-wide (1). PCOS is associated with hyperandrogenemia/ hyperandrogenism, anovulation, infertility, and a characteristic ovarian morphology consisting of multiple small subcortical follicular "cysts" embedded in bilaterally enlarged ovaries (2-5). The presence of elevated circulating concentrations of testosterone results primarily from increased production of androgens by the ovaries, and is a classic endocrine phenotype of women with PCOS. Although there has been debate about the diagnostic criteria for PCOS, hyperandrogenemia/hyperandrogenism and anovulation, not explained by other causes, is a hallmark of the disorder, and is included as a key element in all "consensus" diagnosis schemes (6-10).
P olycystic ovary syndrome (PCOS) is one of the most common endocrinopathies affecting 5-7% of reproductive age women world-wide (1) . PCOS is associated with hyperandrogenemia/ hyperandrogenism, anovulation, infertility, and a characteristic ovarian morphology consisting of multiple small subcortical follicular "cysts" embedded in bilaterally enlarged ovaries (2) (3) (4) (5) . The presence of elevated circulating concentrations of testosterone results primarily from increased production of androgens by the ovaries, and is a classic endocrine phenotype of women with PCOS. Although there has been debate about the diagnostic criteria for PCOS, hyperandrogenemia/hyperandrogenism and anovulation, not explained by other causes, is a hallmark of the disorder, and is included as a key element in all "consensus" diagnosis schemes (6) (7) (8) (9) (10) .
There is consensus that the ovarian theca cells are the primary source of excess androgen biosynthesis in women with PCOS (11) (12) (13) . Studies on freshly isolated thecal tissue or cultures of theca cells derived from normal and PCOS women have demonstrated that PCOS theca secretes greater amounts of androgen than theca tissue or cells from regularly ovulating women (12, (14) (15) (16) (17) (18) (19) . Increased androgen biosynthesis in PCOS theca cells results from increased expression of the key enzymes involved in androgen biosynthesis, steroid-17-α-hydroxylase/17,20 lyase (encoded by the CYP17A1 gene) and cholesterol side-chain cleavage enzyme, mitochondrial (encoded by the CYP11A1 gene) (15) (16) (17) 20) .
PCOS is a heterogeneous disorder that shows evidence of genetic predisposition among affected individuals (21, 22) . Despite the semblance to an autosomal dominant inheritance, an oligogenic/polygenic model most likely contributes to the underlying pathophysiology (23, 24) . Incomplete penetrance, epigenetic modification, and environmental contributions have hindered attempts to clarify the underlying model of inheritance. Despite advances in genetic technologies, very few PCOS susceptibility genes have been validated. Numerous candidate geneassociation studies have been conducted, but few have yielded statistically significant associations that have been replicated (25) .
The first genome-wide association studies (GWAS) and subsequent follow up performed on Han Chinese populations identified the following PCOS candidate loci: DENND1A, insulin receptor (INSR), YAP1, C9orf3, RAB5B, HMGA2, TOX3, SUMO1P1/ZNF217, THADA, follicle stimulating hormone receptor (FSHR), luteinizing hormone/choriogonadotropin receptor (LHCGR) (23, 24) . The identification of the DENND1A locus at 9q22.32 has been replicated in both Asian and European populations (26) (27) (28) (29) , hence DENND1A has gained recognition as a strong PCOS susceptibility gene (30) . DENND1A is a member of a family of 18 human genes, termed "connecdenns." These proteins contain differentially expressed in normal and neoplastic
Significance
Family-based studies revealed that polycystic ovary syndrome (PCOS), a common endocrinopathy of women, has a genetic basis. Genome-wide association studies identified DENND1A as a PCOS locus, but its role in PCOS was unknown. We report that an alternatively spliced form of DENND1A (DENND1A.V2) is increased in PCOS theca cells, the source of the excess androgens that characterizes PCOS. Forced expression of DENND1A.V2 in normal theca cells increased expression of genes encoding steroidogenic enzymes, leading to augmented androgen biosynthesis, whereas silencing of DENND1A.V2 in PCOS theca cells reverts them to a normal phenotype. Our findings establish that increased DENND1A.V2 expression is sufficient to promote a PCOS phenotype in human theca cells, information that can inform development of diagnostic tests as well as novel therapeutic interventions.
cells domains (DENN domains). The DENN domain is tripartite, consisting of a u-DENN (upstream DENN domain), DENN (core DENN domain), and d-DENN (downstream DENN domain) separated by "linker" sequences. The DENN domains function as Rab-specific guanine nucleotide-exchange factors (31, 32) . The DENND1A gene consists of 22 exons extending over 500,000 bases, and encodes protein connecdenn 1, which has a clathrinbinding domain and is thought to facilitate endocytosis and receptor-mediated turnover (31, 33, 34) . Connecdenn 1 is a guanine nucleotide-exchange factor that interacts with members of the Rab family of small GTPases, which are involved in membrane trafficking (31) . Connecdenn 1 is associated with lipids, particularly phosphoinsitol-3-phosphate and other endocytosis/endosome proteins (31) . DENND1A encodes two transcripts as a result of alternative splicing (31) . The longer of these transcripts, DENND1A variant 1 (DENND1A.V1), encodes a 1,009-aa protein with C-terminal proline-rich domain; the other, DENND1A variant 2 (DENND1A.V2), encodes a truncated 559-aa protein that contains the DENN domain and the clathrin-binding domain, but lacks the proline-rich domain and includes a C-terminal 33-aa sequence that is not found in the larger connecdenn 1 variant. Until recently, little has been known about DENND1A expression in cells and tissues related to reproduction, with the exception that it is expressed in testes, theca cells, and H295 adrenal carcinoma cells: cells that make androgens (25) .
Although the association of the DENND1A locus in PCOS has been confirmed in populations of European ancestry in multiple studies (26, 27) , it is not known how DENND1A and the other candidate gene loci and their pathophysiological significance might contribute to the PCOS phenotype and the mechanism by which any of these genes might promote PCOS. Moreover, it is unclear how the functional variants of DENND1A contribute to disease risk.
We have developed conditions to propagate theca cells isolated from individual, size-matched follicles from ovaries of normal cycling and PCOS women, to our knowledge providing the first evidence that successively passaged PCOS theca cells retain the ability to produce augmented levels of androgens and progesterone compared with normal theca cells (15, 16, 35) . This increased androgen and progesterone biosynthesis in PCOS theca cells have been attributed, in part, to increased CYP17A1 and CYP11A1 gene transcription and RNA stability (17, 20, 36) . Our molecular characterization of normal and PCOS theca cells from multiple individuals by microarray analysis and quantitative PCR (qRT-PCR) also established that normal and PCOS cells have distinctive molecular signatures (16, 37, 38) . These findings are consistent with the notion of an intrinsic abnormality in PCOS theca that promotes hypersecretion of androgens in response to tropic stimulation. Our theca cell-culture system provides a unique platform for identifying the biochemical and molecular mechanisms underlying genetic abnormalities identified in PCOS women.
To our knowledge, this report presents the first data to demonstrate that the alternatively spliced, truncated form of DENND1A, DENND1A.V2, is differentially expressed in normal and PCOS theca cells. We provide previously unidentified data to show that DENND1A.V2 contributes to the pathophysiological state of increased CYP17A1 and CYP11A1 gene expression and augmented androgen and progestin biosynthesis by PCOS theca cells, which is a hallmark of PCOS.
Results

DENND1A.V2 Protein Expression Is Increased in PCOS Theca Cells.
To examine whether the alternatively spliced forms of DENND1A are differentially expressed in normal and PCOS theca cells, Western blot analysis was performed on whole-cell extracts from theca cells isolated from normal and PCOS women that were grown until subconfluent and transferred into serum-free medium treated with and without 20 μM forskolin, an activator of adenylate cyclase, for 24 h. An N-terminal DENND1A antibody (Sigma) was used, and we expected bands at ∼112 kDa, corresponding to DENND1A.V1, and 62 kDa, corresponding to DENND1A.V2. As shown in Fig. 1A , a representative Western blot analysis demonstrated increased 62-kDa DENND1A.V2 in PCOS theca cells treated under both basal and forskolin-stimulated conditions compared with normal theca cells. However, the 112-kDa DENND1A.V1 was not significantly increased in PCOS theca cells. In Fig. 1B , cumulative analysis of whole-cell lysates harvested from theca cells isolated from five independent normal and five independent PCOS subjects, demonstrated that DENND1A.V2 protein is significantly increased in PCOS theca cells compared with normal theca cells under both control and forskolinstimulated conditions. Forskolin treatment did not appear to affect DENND1A.V2 protein accumulation in normal or PCOS theca cells. In contrast, cumulative analysis of DENND1A.V1 in normal and PCOS theca cells showed that DENND1A.V1 protein level was significantly increased by forskolin treatment in normal cells (Fig. 1C) . In addition, in forskolin-stimulated PCOS theca cells, DENND1A.V1 was significantly reduced compared normal cells. The ratio of DENND1A.V2/V1 protein was significantly increased in PCOS theca cells under control and forskolin-stimulated conditions (Fig. 1D ).
DENND1A Immunohistochemical Staining Is Increased in the Ovarian
Theca Compartment. To further examine the localization of DENND1A.V2 in the ovary, we used the paraffin-embedded blocks of ovarian tissue obtained from our normal cycling and PCOS patient populations and the N-terminal antibody for DENND1A protein used in the Western analyses presented in Fig. 1 . As shown in Fig. 2A , immunostaining was prominent in the theca compartment of the ovary (4× magnification), and increased in PCOS theca compared with theca cells in normal ovaries (10× magnification). In Fig. 2B , DENND1A staining in 
PCOS theca and granulosa cells is shown (40× magnification).
Staining is primarily in the PCOS theca nuclei, cytoplasm, and cell membranes, as shown (100× oil magnification) in Fig. 2B . Because the N-terminal antibody predominantly reacts with DENND1A.V2 in Western blotting, and DENND1A.V2 is increased in PCOS theca cells, it is likely that the increased DENND1A immunostaining in PCOS ovaries reflects increased DENND1A.V2.
DENND1A.V2 mRNA Abundance Is Increased in PCOS Theca Cells, and Is Correlated with Increased Androgen Production. The abundance of DENND1A.V2 mRNA was examined in theca cells isolated from six normal and six PCOS patients treated with and without 20 μM forskolin (Fig. 3A) , quantitated by qRT-PCR analysis, and normalized using TATA box binding protein (TBP) mRNA. DENND1A.V2 mRNA was significantly increased under basal and forskolin-stimulated conditions in PCOS theca cells, compared with normal cells. There was no significant increase in DENND1A.V2 mRNA accumulation in response to forskolin stimulation. To examine whether DENND1A.V2 mRNA was associated with increased androgen biosynthesis, we examined dehydroepiandrosterone (DHEA) accumulation in the matched six normal and six PCOS theca cell preparations under the same conditions. As shown in Fig. 3B , normal theca cells with lower DHEA synthesis have reduced DENND1A.V2 mRNA, whereas the increase in basal and forskolin-stimulated DHEA production in PCOS theca cells is associated with increased DENND1A.V2 mRNA abundance.
Urine Exosomal DENND1A.V2 mRNA Is Increased in PCOS Women.
Exosomes are small vesicular nucleic acid that are shed into blood and urine, and provide a stable source of RNA. Thus, to examine whether increased DENND1A.V2 in PCOS theca cells reflects corresponding increases in systemic DENND1A.V2 mRNA accumulation in PCOS women, we examined exosomal mRNA isolated from midday urine samples from multiple normal cycling and well-characterized PCOS women by qRT-PCR, as described in SI Materials and Methods. As shown in Fig. 4 , and in agreement with our qRT-PCR in PCOS theca cells, DENND1A.V2 mRNA is significantly increased in urine exosomes isolated from PCOS, compared with normal cycling women.
Forced Expression of DENND1A.V2 Increases Normal Theca Cell
Steroidogenesis. An adenovirus expressing human DENND1A. V2 was used to test the hypothesis that increased expression of DENND1A.V2 converts normal theca cells to a PCOS phenotype of increased androgen and progesterone production. In these experiments normal theca cells were infected with 0.3, 1.0, 3.0, and 10 pfu per cell of either empty (null-pAdenoG) or DENND1A.V2 expressing (hDENND1A.V2-pADenoG) adenovirus, treated with or without 20 μM forskolin in serum-free medium. Following 72 h of treatment, DHEA in the media was quantitated. Infection with all doses of DENND1A.V2 adenovirus significantly increased forskolin-stimulated DHEA production compared with control adenovirus (Fig. 5A ). Western blot analysis following infection of null and DENND1A adenovirus was performed to confirm that DENND1A.V2 protein is overexpressed, consistent with our studies on cultured theca cells (Fig. 5B) . In subsequent experiments, we investigated the effects of infection of theca cells from several individual normal women with 3 pfu of control adenovirus or adenovirus expressing DENND1A.V2 on DHEA (Fig.  5C ), 17α-hydroxyprogesterone (17OHP4) (Fig. 5D ), testosterone (T) (Fig. 5E ), and progesterone (P4) (Fig. 5F ). DENND1A.V2 adenovirus infection significantly increased basal 17OHP4, T, and P4 accumulation compared with control adenovirus. In addition, DENND1A.V2 adenovirus infection significantly increased forskolin-stimulated DHEA, 17OHP4, and P4 compared with control adenovirus. Thus, forced expression of DENND1A.V2 in normal theca cells, converted the cells to a PCOS phenotype of increased androgen and progestin biosynthesis. Gene Expression in Normal Theca Cells. To examine the effects of DENND1A.V2 expression on CYP17 and CYP11A1 mRNA accumulation, normal theca cells were infected with 3 pfu DENND1A.V2 adenovirus or null adenovirus, and treated with or without 20 μM forskolin for 16 h. Following treatment, RNA was harvested, and CYP17 and CYP11A1 mRNA abundance was quantitated and normalized by TBP abundance. Both CYP17 mRNA ( Fig. 6A ) and CYP11A1 mRNA (Fig. 6B ) accumulation were significantly increased following 3 pfu per cell DENND1A. V2 infection under forskolin-stimulated conditions, compared with infection with control adenovirus.
To examine the effects of DENND1A.V2 on CYP17A1 transcription, normal theca cells were transfected with pGl3 luciferase reporter plasmid containing −770/+44 of the 5′-flanking regions of the human CYP17A1 gene (−770 CYP17A1/LUC) using the calcium phosphate method (17, 36) . Following transfection the cells were infected with the DENND1A.V2 adenovirus or control adenovirus for 1 h, and treated with serum-free medium with and without 20 μM forskolin, an activator of adenylate cyclase. Twentyfour hours later, luciferase activity was determined. Transfections were performed in triplicate and normalized for transfection efficiency using β-galactosidase. Fig. 6C shows that 3 pfu per cell DENND1A.V2 adenovirus infection increases both basal and forskolin-stimulated −770 CYP17A1/LUC promoter activity compared with control adenovirus. The −770 CYP17A1/LUC was used based on our prior reports demonstrating that the 5′ −770/+44 bp flanking sequence of the CYP17A1 gene confers increased transcriptional regulation in PCOS theca cells (17, 36) . The results of the above studies showed that DENND1A.V2 significantly increased −770 CYP17A1/LUC promoter function in normal theca cells, converting the cells to a PCOS phenotype. Similar results were observed with a reporter construct containing −235/+44 of the 5′ flanking sequence of the CYP17A1 gene (−235 CYP17A1/ LUC), which also confers increased transcriptional regulation in PCOS theca cells (17, 36) .
We used a CYP11A1 pGl3 reporter construct containing the −160/ −90 bp element of the proximal CYP11A1 promoter (−160/−90 CYP11A1/LUC), which confers increased CYP11A1 expression in PCOS theca cells (20) to examine the effects of DENND1A.V2 on CYP11A1 transcription in theca cells. Normal theca cells were transfected with the −160/−90 CYP11A1/LUC plasmid with a DENND1A.V2/pCMV-XL4 or empty pCMV-XL4. Forty-eight hours following transfection the cells were harvested and luciferase was measured. As shown in Fig. 6D, DENND1A .V2 increases forskolin-stimulated −160/−90 CYP11A1/LUC promoter activity compared with empty plasmid. Collectively, these data suggest that the increased theca cell steroidogenesis resulting from augmented DENND1A.V2 expression is at least in part because of transcriptional activation of the CYP17A1 and CYP11A1 genes.
Knock-Down of DENND1A.V2 mRNA in PCOS Theca Cells Reduces CYP17A1 and CYP11A1 Expression, Androgen, and Progesterone Production. To determine the effect of knock-down of endogenous DENND1A.V2 mRNA on CYP17 and CYP11A1 mRNA .V2 infection increased basal 17OHP4 (*P < 0.01), T (*P < 0.05), and P4 (*P < 0.05) accumulation compared with control Null adenovirus. DENND1A.V2 infection also increased forskolin-stimulated DHEA (*P < 0.001), 17OHP4 (**P < 0.001), and P4 (**P < 0.001) compared with control Null adenovirus. levels, silencing DENND1A.V2 shRNA plasmids were transfected into PCOS theca cells, and basal and forskolin-stimulated CYP17 mRNA was assessed using qRT-PCR. In these experiments PCOS theca cells were transfected with pRSV-scrambled plasmid or plasmids specific to DENND1A.V2 (pSV-shRNA1 or pRSV-shRNA2). Six hours following transfection, the cells were treated with and without 20 μM forskolin and, 24 h later, total RNA was harvested, and CYP17, CYP11A1, and TBP mRNA abundance was measured. As shown in Fig. 7A, DENND1A .V2 shRNA1 and shRNA2 retrovirus plasmid significantly inhibited both basal and forskolin-stimulated CYP17 mRNA accumulation in PCOS theca cells. Both of the DENND1A.V2 shRNA plasmids also significantly inhibited forskolin-stimulated CYP11A1 mRNA (Fig. 7B) in PCOS theca cells.
Parallel studies were performed to evaluate whether silencing shRNAs specific to DENND1A.V2 would inhibit CYP17A1 promoter function (i.e., transcription) in PCOS theca cells. PCOS theca cells were transfected with a CYP17A1 luciferase reporter plasmid (−235 CYP17A1/LUC) containing −235/+44 of the CYP17A1 promoter fused to the luciferase gene in pGL3. Scrambled pRV expression vector or plasmid encoding the silencing DENND1A.V2 pRV-shRNA1 or pRV-shRNA2 was also added to the transfection mixture. Six hours following transfection, the cells were rinsed with PBS, and treated in serum-free medium with and without 20 μM forskolin. Twenty-four hours later luciferase activity was determined. The results from these experiments showed that transfection of DENND1A.V2 shRNA1 inhibited basal and cAMP-dependent CYP17A1 reporter activity in PCOS theca cells compared with scrambled shRNA. As we previously reported, we observed an increase in both basal and forskolin-stimulated −235 CYP17A1/LUC promoter regulation in PCOS theca cells (36) . As shown in Fig. 7C , cotransfection of −235 CYP17A1/LUC with a silencing DENND1A.V2 shRNA1 or shRNA2 resulted in a significant reduction of forskolindependent CYP17A1 reporter activity in PCOS theca cells, compared with scrambled shRNA.
Silencing of DENND1A.V2 Expression by shRNA Lentivirus Particles Inhibits PCOS Theca Cell Steroidogenesis. To evaluate the effect of knockdown of DENND1A.V2 on steroid biosynthesis, we used custom Thermo/Dharmacon GIPZ DENND1A.V2 shRNA particles. PCOS theca cells were infected with 300,000 particles per well of silencing shRNA DENND1A.V2 lentivirus or a control nonsilencing lentivirus in serum-free medium. Six hours later the lentivirus mixture was removed and the cells were transferred into serum-free medium in the presence or absence of forskolin for 72 h. Infection with silencing shRNA DENND1A.V2 lentivirus significantly inhibited forskolin-stimulated 17OHP4 (Fig.  7D ), DHEA biosynthesis (Fig. 7E) , and P4 (Fig. 7F) . Although there was a trend toward inhibition in basal steroidogenesis following DENND1A.V2 lentivirus infection, the design of lentiviral infection experiments precluded the accurate assessment of basal steroid concentrations.
Anti-DENND1A.V2-Specific IgG Reduces DHEA Secretion and CYP17 mRNA in PCOS Theca Cells. DENND1A is known to be associated with the cell membrane and clathrin-coated pits (31, 33), potentially making DENND1A epitopes available to antibodies added to the cell exterior. We generated a rabbit polyclonal antibody against a 21-aa peptide ([C]-QKSITHFAAKFPTRGWTSSSH) that is specific to DENND1A.V2. Western blot analysis demonstrating the specificity of this polypeptide antibody to the 62-kDa form of DENND1A.V2, and increased expression in PCOS theca cells, is provided in Fig. S1 . This DENND1A.V2-specific IgG was added to the culture medium of normal and PCOS theca cells to determine whether it could be used to block or neutralize DENND1A.V2 function, and thus alter steroid biosynthesis in normal and PCOS theca cells. In these experiments, PCOS theca cells were treated with increasing concentrations of a DENND1A.V2 isoform-specific IgG or nonspecific IgG, in the presence or absence of 20 μM forskolin. As shown in Fig. 8A , DENND1A.V2 IgG significantly inhibits forskolinstimulated DHEA biosynthesis, with an approximate ID 50 of 0.25 μg/mL In contrast, nonspecific IgG had no effect on DHEA biosynthesis. Subsequent experiments were performed to examine the effects of 0.5 μg/mL of DENND1A.V2-specific IgG or 0.5 μg/mL nonspecific IgG on CYP17 mRNA (Fig. 8B ) and CYP11A1 mRNA (Fig. 8C ) accumulation following 16-h treatment in the presence and absence of 20 μM forskolin in normal and PCOS theca cells from various individual patients. The data in Fig. 8B demonstrate that 0.5 μg/mL DENND1A.V2-specific IgG significantly inhibits CYP17 mRNA accumulation in PCOS theca cells, under control and forskolin-stimulated conditions following 16 h of treatment. In contrast, in normal theca cells, DENND1A.V2 IgG had no effect on basal or forskolin-stimulated CYP17 mRNA (Fig. 8B) . As shown in Fig. 8C, DENND1A .V2-specific IgG also significantly inhibited forskolin-stimulated CYP11A1 mRNA accumulation in PCOS theca cells, but had no effect on CYP11A1 mRNA accumulation in normal theca cells.
In parallel experiments, normal and PCOS theca cells from individual patients were treated with 0.5 μg/mL of DENND1A. V2-specific IgG or 0.5 μg/mL or nonspecific IgG and basal and forskolin-stimulated absence DHEA (Fig. 8D), 17OHP4 (Fig. 8E) , and P4 (Fig. 8F) biosynthesis on a per cell basis was measured following 72-h treatment. The results of these experiments showed that DENND1A.V2-specific IgG significantly inhibited forskolin-stimulated DHEA (Fig. 8D) and 17OHP4 (Fig. 8E) , in PCOS theca cells by 50% compared with control IgG, without affecting normal theca cells.
Discussion
Studies conducted over the past decade have built a convincing argument that genetic factors contribute to PCOS. Despite advances in genetic technologies, very few PCOS susceptibility genes have been validated. Numerous candidate gene-association studies had been conducted, and a number of these have yielded statistically significant associations of variants with PCOS (25) . These include studies using family-based methods, like the transmissiondisequilibrium test, which test for both association and linkage (39) . However, the candidate gene studies have been uniformly conducted on small sample populations and have had limited statistical power. Additionally, few of these studies have yielded sufficiently robust results that have been consistently replicated by different investigators studying different populations.
Important milestones in PCOS genetics were achieved with the publication of GWAS on Han Chinese populations that identified PCOS candidate loci: DENND1A, INSR, YAP1, C9orf3, RAB5B, HMGA2, TOX3, SUMO1P1/ZNF217, THADA, and FSHR/ LHCGR (23, 24) . The initial study encompassed a total of 4,082 cases and 6,678 controls, with cases defined according to the "Rotterdam Criteria." The replication of the association of SNPs in the DENND1A locus with PCOS in different populations by different investigators provides strong support for DENND1A as a PCOS candidate gene (26) (27) (28) (29) . However, before our studies there was no pathophysiological link between DENND1A and the other GWAS loci to reproduction or ovarian function. In addition, the specific variants encoded by DENND1A loci that contribute to PCOS phenotype of increased androgen production and disease risk are unknown.
We have, to our knowledge, carried out the first studies to examine the expression of DENND1A in well-characterized theca cells from normal cycling and PCOS women. The finding that increased expression of a splice variant of DENND1A RNA, DENND1A.V2, is characteristic of PCOS theca cells provided a basis for pursuing studies on the functional consequences of this molecule in terms of theca cell function. Forced expression of DENND1A.V2 in normal theca cells increases CYP17A1 and CYP11A1 gene expression and converts the cells to a PCOS phenotype of augmented androgen and progestin biosynthesis. In contrast, knock-down of DENND1A.V2 with silencing shRNA plasmids or lentivirus in PCOS theca cells reverts the cells to a normal phenotype of reduced CYP17A1 and CYP11A1 gene expression and androgen and progestin biosynthesis. These observations suggest that DENND1A is involved in a signaling cascade that augments transcription of steroidogenic genes that subsequently results in increased androgen production.
What are the possible mechanisms of DENND1A.V2 action? DENND1A.V2 is a truncated connecdenn 1, which has a clathrinbinding domain and is thought to facilitate endocytosis. Among the loci associated with PCOS in Han Chinese, several reside in or near genes that potentially define a network, including FSHR, LHCGR, and INSR, which encode receptors that reside on the plasma membrane and which are internalized by clathrin-coated pits, where the DENND1A protein is located (24, 25, 33) . The DENN domains of DENND1A function as Rab-specific guanine nucleotide-exchange factors. Ras related protein 5B (RAB5B), another PCOS GWAS candidate, is a Rab-GTPase, also thought to be involved in endocytosis and receptor recycling and could, therefore, be a molecule interacting with the DENN domain (40, 41) . RAB5B signaling has also been reported to involve PI3K, PKB, and MAPK/ERK components (33, (40) (41) (42) . Therefore, the truncated form of DENND1A.V2 could potentially affect insulin or luteinizing hormone (LH)-receptor turnover and sensitivity in theca and granulosa cells, further affecting ovarian function and steroid biosynthesis in PCOS women. DENND1A has also been shown to be associated with lipids, particularly phosphoinsitol-3-phosphate, and other endocytosis/endosome proteins (31, 34) , and could potentially be involved in insulin and LH-receptor signaling. Alternatively, DENND1A.V2 may have a more direct role in controlling gene expression. The observation of DENND1A.V2 localization in the nucleus of theca cells suggests that DENND1A. V2 translocates into the nucleus, possibly by a process that is facilitated by RAB5B, another GWAS-discovered PCOS candidate, where it may be involved in transcriptional activation of CYP17A1 and CYP11A1.
Our studies with a specific anti-DENND1A.V2 IgG suggest that DENND1A.V2 epitopes are available to extracellular antibodies. The observation that augmented CYP17 and CYP11A mRNA and androgen biosynthesis in PCOS theca cells can be reduced using DENND1A.V2-specific IgG raises the possibility that humanized monoclonal antibodies against DENND1A.V2 may be a useful biologic therapeutic agents for the hyperandrogenemia associated with PCOS, and possibly other phenotypes related to insulin action.
We demonstrated that DENND1A.V2 mRNA was significantly increased in urine exosomal mRNA from PCOS women, compared with normal cycling women. Exosomes are small vesicles of about 40-100 nm that are secreted from cells into extracellular fluid, and are found in different bodily fluids, such blood, blood derivatives, urine, and amniotic fluid. Exosomes are produced by all cell types and have a molecular phenotype, which largely reflects that of a parent cell (43, 44) The contents of exosomes reflect the origin and the physiological status of the source cells, and thus exosomal RNAs, such as DENND1A.V2, can serve as biomarkers for various diseases. These data further confirm our findings in that DENND1A.V2 mRNA is increased in PCOS, and provide the basis for a potential noninvasive diagnostic for PCOS. The source of the urine exosomal DENND1A mRNA is not known. The kidney expresses the DENND1A gene, and it is a likely source (26, 33) . If this is indeed the case, the finding of increased DENND1A.V2 mRNA in urine speaks to a generalized alteration in expression of this variant in PCOS.
What is the genetic mechanism resulting in increased DENND1A.V2 expression in PCOS? The DENND1A SNPs reported to be associated with PCOS in the GWAS, and those from replication studies, lie in intronic regions and are not associated with canonical sites for DENND1A expression or splicing. The fact that DENND1A.V2 expression is increased in PCOS suggests that there must be a gain-of-function variation, which could be related to copy-number variants, variation in the promoter region that increases promoter activity, variants that affect splicing, or mRNA stability. Moreover, because the odds ratio for DENND1A association with PCOS is modest (<2.0), it is likely that variation in other genes other than the DENND1A locus accounts for the consistent elevation of DENND1A.V2 expression (e.g., transcription factors controlling DENND1A promoter function). In an initial attempt to identify functional genetic variants in the DENND1A locus, we performed wholeexome sequencing (Table S1 ) as presented in Fig. S1 . We found only synonymous coding-sequence variants, and no missense or nonsense variants. This result is consistent with a recent wholeexome sequencing study reporting no changes in DENND1A exons or splice junctions in PCOS patients (45) . Intronic sequences captured in the whole-exome sequencing also contained variants, some of which were only found in PCOS genomic DNA. None of these were in introns, where it was likely that splicing to generate DENND1A.V2 could be affected. However, we cannot exclude at this time the possibility that these variants contribute to increased DENND1A.V2 expression because they lie in enhancer elements or have long-range effects on promoter function or splicing. The DENND1A.V2 locus also encodes a microRNA, miR601. We have characterized the microRNA profiles of normal and PCOS theca cells and found no differences in miR601 expression. Moreover, none of the SNPs identified in wholeexome sequencing appear to affect miR601 structure. Another possibility that remains to be explored is whether genetic variation in the DENND1A promoter contributes to increased DENND1A expression. The promoter is GC-rich, and therefore variation could also affect epigenetic control through altered DNA methylation. Alternatively, copy-number variation could result in increased DENND1A expression. Thus, at this juncture the genetic mechanism underlying the consistent overexpression of DENND1A in PCOS remains elusive.
In conclusion, we have demonstrated that a splice variant (DENND1A.V2) derived from the DENND1A gene, a gene implicated in the pathogenesis of PCOS from GWAS and replication studies, has a functional role in controlling theca cell steroidogenesis. We have established that overexpression of DENND1A.V2 is sufficient to convert normal theca cells into a PCOS biochemical phenotype characterized by increased CYP17A1 and CYP11A1 gene expression and augmented androgen and progestin production, and that suppression of DENND1A.V2 function pushes PCOS theca cells toward normal phenotype in terms of steroidogenic enzyme gene expression and steroid production. The fact that DENND1A.V2 mRNA is elevated in urine of women with PCOS and that a DENND1A.V2-specific IgG can transform the biochemical characteristics of PCOS theca cells, reducing steroidogenesis, opens up new possibilities for noninvasive detection of PCOS and biological therapy.
Materials and Methods
Normal and PCOS Theca Cells. Human theca interna tissue was obtained from follicles of women undergoing hysterectomy, following informed consent under a protocol approved by the Institutional Review Board of The Pennsylvania State University College of Medicine. As a standard of care, oophorectomies were performed during the luteal phase of the cycle. Theca cells from normal cycling and PCOS follicles were isolated and grown as we have as previously reported in detail (20, 46, 47) . The theca cell preparations used in these studies have been described and characterized previously (15-17, 20, 35-38, 47) . The steroidogenic phenotypes of the normal and PCOS theca cells have been reported to result from the inherent properties of the cells, rather than the cycle phase at the time that they were isolated (15, 17, 48) . PCOS and normal ovarian tissue came from age-matched women, 38-40 y old. The diagnosis of PCOS was made according to National Institutes of Health (NIH) consensus guidelines (10, 49) , which include hyperandrogenemia, oligoovulation, polycystic ovaries, and the exclusion of 21-hydroxylase deficiency, Cushing's syndrome, and hyperprolactinemia. All of the PCOS theca cell preparations studied came from ovaries of women with fewer than six menses per year and elevated serum total testosterone or bioavailable testosterone levels (15, 17, 48) . Each of the PCOS ovaries contained multiple subcortical follicles of less than 10 mm in diameter. The control (normal) theca cell preparations came from ovaries of fertile women with normal menstrual histories, menstrual cycles of 21-35 d, and no clinical signs of hyperandrogenism. Neither PCOS nor normal subjects were receiving hormonal medications at the time of surgery. Indications for surgery were dysfunctional uterine bleeding, endometrial cancer, and pelvic pain. Experiments comparing PCOS and normal theca were performed using fourthpassage (31-38 population doublings) theca cells isolated from individual size-matched follicles obtained from age-matched subjects, in the absence of in vivo stimulation. The use of fourth-passage cells allowed us to perform multiple experiments from the same patient population, and were propagated from frozen stocks of second passage cells in the media described above. For all studies, theca cell cultures obtained from at least five independent normal and five independent PCOS patients were examined. The passage conditions and split ratios for all normal and PCOS cells were identical.
Quantitative DENND1A.V1, DENND1A.V2, CYP17, and CYP11A1 qRT-PCR. Quantitation of DENND1A.V1 and V.2, CYP17, and CYP11A1 mRNA abundance was determined using the Single Step Brilliant III Ultra Fast qRT-PCR Reagents (Agilent) using 50-100 ng total RNA/tube, and 200-nM final concentration of each forward and reverse primers and 100-nM probe. The specific primer and probe sequences used are provided in detail in SI Materials and Methods. DENND1A.V2 data were verified with the second confirmatory DENND1A.V2 primer probe set provided. The gene-specific one-step PCR was carried out in duplicate for each mRNA sample and for a series of dilutions in an Mx3000p Thermocycler system (Stratagene) according to the manufacturer's instructions for this instrument, as previously described (20) . The same process was carried out for TBP to use TBP values for normalization of each reaction. The mean target value for each unknown was divided by the mean TBP value to normalize each sample.
Exosomal RNA Extraction and Purification. Midday urine samples were obtained from five normal women and six women with PCOS, using the same clinical criteria described above for normal and PCOS theca cells, according to NIH consensus guidelines (10, 49) . Following informed consent under an Institutional Review Board protocol approved by the Institutional Review Board of The Pennsylvania State University College of Medicine. The urine samples were collected and placed at 4°C until processed. Cleared urine was frozen at −80°C and extracted using a modified protocol of the "Urine Exosome RNA Isolation Kit" from Norgen. The resulting RNA was quantified using a Nano-drop. DENND1A.V2 mRNA was then quantitated by qRT-PCR, and normalized using 5S mRNA abundance.
Quantitation of Steroid Biosynthesis. ELISAs for DHEA, 17OHP4, T, and P4 were performed without organic solvent extraction using kits from DRG International, as described by the manufacturer's protocol, and normalized by cell count. Information pertaining to the specificity and cross-reactivity of the specific ELISAs for the DHEA, 17OHP4, T, and P4 is provided in SI Materials and Methods.
Western Blot Analysis. Western blot analysis was performed on 35 μg/ln whole-cell lysates harvested from fourth-passage normal and PCOS theca cells were grown until subconfluent and transferred into serum-free medium with and without forskolin for 24 h, as we have previously described (48) . Similar results were obtained in Western analyses performed using Abcam antibody specific for the N-terminal and Sigma antibody for intrapeptide sequence of DENND1A, which were visualized using ECL (Pierce). DENND1A Western data were quantitated and normalized by total mammalian target of rapamycin (mTOR), which is not significantly different in normal and PCOS theca cells, nor regulated by forskolin treatment. Actin and GAPDH cannot be used to normalize Westerns as they are regulated by forskolin in theca cells and are differentially expressed in normal and PCOS cells.
Immunohistochemical Localization of DENND1A. Immunohistochemical (IHC) analysis for DENND1A was performed on 4-to 5-μm-thick sections of formalin-fixed, paraffin-embedded tissue on a Ventana Discovery XT stainer (Ventana Medical Systems), using a the Sigma DENND1A antibody that we found to react predominantly with DENND1A.V2 in the Western blotting, as shown in Fig. 1A . The staining protocol consisted of incubation in the primary antibody for 30 min at 1:300 dilution, followed by detection and visualization with Ventana OmniMap DAB anti-Rabbit detection kit (Ventana Medical Systems). FFPE samples of adrenal cortex were used as a positive tissue control. After using various antigen retrieval methods and examining several serial dilutions of the DENND1A.V2 polypeptide antibody (made against the DENND1A.V2 21 amino acid sequence [C]-QKSITHFAAKFPTRGWTSSSH), we could not obtain specific immunostaining.
Replication-Deficient Adenovirus Infections. DENND1A.V2 adenovirus (hDENND1A. V2-pADenoG) was constructed by Applied Biological Materials by cloning DENND1A.V2 from pCMV6-XL4 plasmid encoding the DENND1A.V2 into pADenoG, from Origene. Control empty null nonexpressing adenovirus (pAdenoG-null) was also obtained from Applied Biological Materials.
Recombinant adenoviruses were propagated and expanded in HEK293T cells, purified using a Virabind Adenovirus Miniprep Kit, Cell Biolabs, and tittered by QuickTiter Adenovirus Titer Elisa Kit, Cell Biolabs. Both the DENND1A. V2 or Control empty null nonexpressing adenovirus (pAdenoG-null) were used to infect in normal theca cells as we previously described (47) .
Transient Transfection of Normal and PCOS Theca Cells. Human theca cells isolated from normal cycling women and women with PCOS were transfected using the calcium phosphate precipitation method as we have previously described (17, 36, 50) . The calcium phosphate precipitate contained 2 μg per dish of luciferase plasmid, and 0.1 μg per dish of an expression vector for β-galactosidase, pSVβ-gal (Promega) for each 30-mm well. Luciferase activity was quantitated and normalized by β-Galactosidase activity as we have previously described (20, 36) . Transfections were performed in triplicate in theca cells isolated from four or more independent normal, and four or more independent PCOS patients.
Statistical Analysis. Data are presented and described in the text as the mean ± SEM performed in triplicate. The results from qRT-PCR, steroid, and transfection analyses were collected from individual patients and ANOVA was performed using Prism 5.0c (GraphPad Software). P values were determined by the Boniferri method for multiple comparisons when significant differences were indicated by ANOVA.
